Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr. Cohen Discusses Entrectinib in Head and Neck Cancer

October 26th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Role of Immunotherapy Expanding in Head and Neck Cancer

October 25th 2017

Ezra Cohen, MD, discusses the role of immunotherapy, the potential of entrectinib, and the importance of multidisciplinary teams for the treatment of patients with head and neck cancer.

Durvalumab Has Emerging Role in Head and Neck Cancer

October 24th 2017

Daniel Zandberg, MD, discusses results from the HAWK study as well as current combination approaches for patients with head and neck cancer.

Photodynamic Therapy: Looking at Treatment of Early-Stage Oral Cancer in a New Light

October 24th 2017

Although surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.

Number of Metastatic Nodes a Predictor for Survival in Oral Cancer

October 24th 2017

The presence of metastatic lymph nodes was directly correlated with poorer survival in patients with oral cancer, according to findings published in the Journal of Clinical Oncology.

NICE Rejects Treatments for Bladder and Thyroid Cancer

October 21st 2017

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

Dr. Gold on the Current State of HPV-Related Head and Neck Cancer

October 19th 2017

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, discusses the current state of human papilloma virus (HPV)-related head and neck cancer.

Dr. Zandberg on Biomarker Development in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Dr. Zandberg on the Role of Immunotherapy in Head and Neck Cancer

October 18th 2017

Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

Dr. Zandberg on the Role of Durvalumab in Head and Neck Cancer

October 14th 2017

Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal Cancer

October 5th 2017

The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

September 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

Dr. Zandberg on Durvalumab Trial in Head and Neck Cancer

September 22nd 2017

Dan Zandberg, MD, assistant professor, medicine, University of Maryland School of Medicine, discusses the HAWK trial of durvalumab (Imfinzi) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Burtness Discusses Next Steps With Immunotherapy in Head and Neck Cancer

September 19th 2017

Barbara A. Burtness, MD, discusses the current role of immunotherapy in head and neck cancer and potential combination regimens on the horizon.

Mixed Results for Pembrolizumab in Phase III HNSCC Study

September 13th 2017

Pembrolizumab (Keytruda) reduced the risk of death compared with standard of care therapy in patients with relapsed/metastatic head and neck squamous cell carcinoma, but the difference fell just shy of statistical significance.

High-Intensity Local Radiation Linked to Improved Survival in HNSCC

September 13th 2017

High-intensity local radiation combined with systemic therapy improved overall survival compared with systemic therapy alone in patients with head and neck squamous cell carcinoma.

Neoadjuvant Nivolumab Reduces Tumor Size Regardless of HPV Status in Head and Neck Cancer

September 10th 2017

Two doses of nivolumab given about 1 month prior to surgery are well tolerated and reduces tumor size in about half of patients with squamous cell carcinoma of the head and neck.

FDG-PET/CT Scanning a Reliable Imaging Surveillance Technique in LAHNSCC

September 8th 2017

18Fluorodeoxyglucose-positron emission tomography/computed tomography scanning reliably detected residual neck disease in newly diagnosed patients with locoregionally advanced head-and-neck squamous cell carcinoma.

Study Supports Active Surveillance for Some Thyroid Cancer Patients

September 6th 2017

Results from an analysis of 3D tumor volume measurements shows papillary thyroid cancers ≤1.5 cm grew slowly during a period of active surveillance, suggesting that surgery may not be necessary for all patients.

Cabozantinib Active as Salvage Therapy in Thyroid Cancer

September 5th 2017

Cabozantinib (Cabometyx) demonstrated durable activity in patients with radioiodine-refractory differentiated thyroid cancer who progressed on VEGFR-targeted therapy.